Amgen, GSK, Regenxbio and others urge SCOTUS to review 'damaging' decision on biomedical patents

The Supreme Court should weigh in on a recent Federal Circuit decision that “defies history and precedent” and could upend the entire biopharma innovation ecosystem, a group of drugmakers and research institutions told SCOTUS in amici briefs this week, backing Bristol Myers Squibb’s bid to re-review a case against Gilead’s Kite Pharma.